Treating high blood pressure, cholesterol, diabetes may lower risk of Alzheimer's disease

May, 2011

New findings reveal that mild cognitive impairment is more likely to develop into Alzheimer’s if vascular risk factors are present, especially if untreated.

A study following 837 people with MCI, of whom 414 (49.5%) had at least one vascular risk factor, has found that those with risk factors such as high blood pressure, diabetes, cerebrovascular disease and high cholesterol were twice as likely to develop Alzheimer's disease. Over five years, 52% of those with risk factors developed Alzheimer's, compared to 36% of those with no risk factors In total, 298 people (35.6%) developed Alzheimer's.

However, of those with vascular risk factors, those receiving full treatment for their vascular problems were 39% less likely to develop Alzheimer's disease than those receiving no treatment, and those receiving some treatments were 26% less likely to develop the disease.

Treatment of risk factors included using high blood pressure medicines, insulin, cholesterol-lowering drugs and diet control. Smoking and drinking were considered treated if the person stopped smoking or drinking at the start of the study.

http://www.eurekalert.org/pub_releases/2011-04/aaon-thb040511.php

Reference:

[2256] Li, J., Wang Y. J., Zhang M., Xu Z. Q., Gao C. Y., Fang C. Q., et al.
(2011). Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease.
Neurology. 76(17), 1485 - 1491.

seniors

Diet

Related News

Controlling diabetes important for slowing cognitive decline

The latest finding from the large, long-running Health, Aging, and Body Composition (Health ABC) Study adds to the evidence that preventing or controlling diabetes helps prevent age-related cognitive decline.

Benefits of omega-3 in preventing age-related cognitive decline not proven

A review of three high quality trials comparing the putative benefits of omega-3 fatty acids for preventing age-related cognitive decline, has concluded that there is no evidence that taking fish oil supplements helps fight cognitive decline.

Alzheimer's risk gene disrupts brain function in older women, but not men

While the ‘Alzheimer’s gene’ is relatively common — the ApoE4 mutation is present in around 15% of the population — having two copies of the mutation is, thankfully, much rarer, at around 2%.

Brief questionnaire for dementia progression validated

Dementia is a progressive illness, and its behavioral and psychological symptoms are, for caregivers, the most difficult symptoms to manage.

Exercise reduces Alzheimer's damage in brain

A study designed to compare the relative benefits of exercise and diet control on Alzheimer’s pathology and cognitive performance has revealed that while both are beneficial, exercise is of greater benefit in reducing Alzheimer’s pathology and cognitive impairment.

Rapamycin makes young mice learn better and prevents decline in old mice

I have reported previously on research suggesting that rapamycin, a bacterial product first isolated from soil on Easter Island and used to help transplant patients prevent organ rejection, might improve learning and memory.

Coffee helps prevent progression to dementia

Following on from mouse studies, a human study has investigated whether caffeine can help prevent older adults with mild cognitive impairment from progressing to dementia.

Alzheimer’s biomarkers present decades before symptoms

A study involving those with a strong genetic risk of developing Alzheimer’s has found that the first signs of the disease can be detected 25 years before symptoms are evident.

Immune system may protect against Alzheimer's

A number of studies have come out in recent years linking age-related cognitive decline and dementia risk to inflammation and infection (put inflammation into the “Search this site” box at the top of the page and you’ll see what I mean). New research suggests one important mechanism.

Effect of blood pressure on the aging brain depends on genetics

I’ve reported before on the evidence suggesting that carriers of the ‘Alzheimer’s gene’, APOE4, tend to have smaller brain volumes and perform worse on cognitive tests, despite being cognitively ‘normal’.

Pages